ARTICLE | Clinical News
Ensituximab: Phase I data
April 22, 2013 7:00 AM UTC
An open-label, dose-escalation Phase I trial in 15 patients with advanced pancreatic and colorectal cancer who progressed on standard therapy showed that 1.5 mg/kg IV ensituximab every 2 weeks for 8 w...